October 16, 2018 • 2 Min

Finding a Safe Dose of a New Drug for Some Types of Solid Tumors

Grayscale image of round lab containers with dark agar medium arranged in rows.

Laineema; Flickr

What is a safe dose of a new drug combined with a standard of care drug for people with advanced pancreatic cancer?

Researchers are testing the safety of the new lab-created LMB-100 using different doses, as well as the safety and effectiveness when it is combined with nab-paclitaxel, a standard treatment for advanced pancreatic cancer. The trial also includes patients with some other types of solid tumors.

What Is LMB-100?

The tumor marker mesothelin is found on the surface of many different types of solid tumors, including pancreatic tumors, as well as in a small number of normal tissues. The drug LMB-100, created (or engineered) in the laboratory, is an immunotoxin. It has two components: one part binds to mesothelin on target cells and the second part is a toxin, which is delivered and released into cancer cells when the drug binds to mesothelin.

Trial Details

Researchers are comparing two different ways of giving patients LMB-100 as they study safety and effectiveness. In one part of the trial, LMB-100 is given intravenously on specific days, with nab-paclitaxel added intravenously on some of those days. Nab-paclitaxel inhibits cell division and promotes cell death and is used to treat advanced pancreatic cancer.

In the other part of the trial, LMB-100 is given intravenously continuously over two to four days. Some participants will also get nab-paclitaxel intravenously on some of those days. The drugs will be given in two 21-day cycles, unless there are severe side effects or the cancer gets worse.

Participants will have blood work, urine tests, and scans throughout the trial to measure the tumor response. They will also be followed after the trial ends, for effectiveness of the treatment and the development of any later side effects.

Qualifying for This Trial

This trial is for patients with recurrent, advanced, or metastatic pancreatic cancer or other solid tumors that have mesothelin on the surface, including mesothelioma. All participants must have had prior chemotherapy. Everyone who qualifies for the trial will receive LMB-100 and some will receive nab-paclitaxel, depending on which part of the trial they are in.

We encourage you to consult your physicians for clinical trials that may be right for you. The website provides more details about this trial as well as many others. You can visit the EmergingMed Trial Finder for a listing of all active pancreatic cancer clinical trials.

This trial has been completed.

Help me find a pancreatic cancer expert near me.

Learn more